Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and metabolic health by targeting the underlying biological mechanisms of aging, today announced that it will present at the 17th World Congress on Targeting Mitochondria 2026, to be held in Berlin from October 21 to 23, 2026.

Kevin Slawin, M.D., Founder and Chief Executive Officer of the Company, will deliver the industry keynote address, "Building on the Foundation of Four: Advancing Mitochondrial-Targeted Geropeptide Medicine." The address will directly follow the academic keynote scheduled to open the conference, "From Mitochondrial Discovery to Approved Therapy: Lessons for the Future of Medicine," to be delivered by Dr. Hazel H. Szeto, discoverer of SS-31 (elamipretide), the first U.S. Food and Drug Administration ("FDA") approved mitochondria-targeted therapeutic.

Following the two addresses, Drs. Slawin and Szeto will co-host a panel discussion exploring the evolution of mitochondrial science from discovery to therapeutic application.

Eos’s approach is based on the hypothesis that addressing fundamental drivers of cellular dysfunction associated with aging may improve physiological function and mitigate the progression of a broad range of age-related conditions.

PTC-2105, Eos’s lead product candidate, is a novel proprietary MitoXcel™ geropeptide designed to modulate mitochondrial function and selectively target senescent cells for self-elimination.

Eos is developing PTC-2105 initially for the treatment of:

  • Sarcopenia, characterized by progressive loss of skeletal muscle mass, strength, and physical function; and
  • Sarcopenic obesity, a condition in sarcopenic patients that includes simultaneous excess adiposity.